Comparison of Mortality and Short-term Outcomes Between Classic, Intubation-surfactant-extubation, and Less Invasive Surfactant Administration Methods of Surfactant Replacement Therapy

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2023 Oct 2

PMID 37780042

Authors

Seung Yeon Kim

Jiseun Lim

Gyu-Hong Shim

Affiliations

Soon will be listed here.

Abstract

Background: Intubation-Surfactant-Extubation (InSurE) and less invasive surfactant administration (LISA) are alternative surfactant replacement therapy methods for reducing the complications associated with invasive mechanical ventilation. This study aimed to compare the Classic, InSurE, and LISA methods in Very-Low-Birth-Weight infants (VLBWIs) in South Korea.

Methods: The Korean Neonatal Network (KNN) enrolled VLBWIs born between January 1, 2019 and December 31, 2020. They were analyzed retrospectively to compare the duration of respiratory support, length of hospitalization, mortality, and short-term outcomes of the three groups.

Results: The duration of invasive ventilator support was shorter in the following order: InSurE (3.99 ± 11.93 days), LISA (8.78 ± 29.32 days), and the Classic group (22.36 ± 29.94 days) ( = 0.014, < 0.01) and InSurE had the shortest hospitalization (64.91 ± 24.07 days, < 0.05) although the results couldn't adjust for confounding factor because of irregular distribution. InSurE had the lower risk of intraventricular hemorrhage (IVH) grade II-IV [odds ratio (OR) 0.524 [95% confidence interval (CI): 0.287-0.956], = 0.035] than in the Classic group. Mortality was lower in the InSurE [OR 0.377 (95% CI: 0.146-0.978), = 0.045] and LISA [OR 0.296 (95% CI: 0.102-0.862), = 0.026] groups than in the Classic group. There was a reduced risk of moderate to severe bronchopulmonary dysplasia (BPD) [OR 0.691 (95% CI: 0.479-0.998, = 0.049), OR 0.544 (95% CI: 0.355-0.831, = 0.005), respectively], pulmonary hypertension [OR 0.350 (95% CI: 0.150-0.817, = 0.015), OR 0.276 (95% CI: 0.107-0.713, = 0.008), respectively], periventricular leukomalacia (PVL) [OR 0.382 (95% CI: 0.187-0.780, = 0.008), OR 0.246 (95% CI: 0.096-0.627, = 0.003), respectively], and patent ductus arteriosus (PDA) with treatment [OR 0.628 (95% CI: 0.454-0.868, = 0.005), OR 0.467 (95% CI: 0.313-0.696, < 0.001) respectively] in the InSurE and LISA groups compared to the Classic group.

Conclusion: InSurE showed the lowest duration of invasive ventilator support, length of hospitalization. InSurE and LISA exhibited reduced mortality and decreased risks of moderate to severe BPD, pulmonary hypertension, PVL, and PDA with treatment compared to the Classic group.

Citing Articles

Increased bronchopulmonary dysplasia along with decreased mortality in extremely preterm infants.

Jeon G, Oh M, Chang Y Sci Rep. 2025; 15(1):8720.

PMID: 40082666 PMC: 11906727. DOI: 10.1038/s41598-025-93466-8.

Do Different Amounts of Exogenous Surfactant Differently Influence Cerebrovascular Instability in a Consecutive Group of Preterm Babies? Preliminary Results from a Single-Center Experience.

Calandrino A, Caruggi S, Vinci F, Battaglini M, Massirio P, Cipresso G Children (Basel). 2024; 11(9).

PMID: 39334621 PMC: 11429964. DOI: 10.3390/children11091088.

Impact of Early Surfactant Administration on Ductus Arteriosus Assessed at 24 h in Preterm Neonates Less than 32 Weeks of Gestational Age.

Cucerea M, Moscalu M, Ognean M, Fagarasan A, Toma D, Marian R Biomedicines. 2024; 12(6).

PMID: 38927343 PMC: 11201054. DOI: 10.3390/biomedicines12061136.

References

Kaniewska U, Gulczynska E . The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants. Dev Period Med. 2019; 23(3):163-171. PMC: 8522404. View

Riechelmann R, Moreira F, Smaletz O, Saad E . Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005; 56(3):286-90. DOI: 10.1007/s00280-004-0998-4. View

Papile L, BURSTEIN J, Burstein R, KOFFLER H . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978; 92(4):529-34. DOI: 10.1016/s0022-3476(78)80282-0. View

Chahin N, Rozycki H . New modes of surfactant delivery. Paediatr Respir Rev. 2021; 43:38-43. DOI: 10.1016/j.prrv.2021.10.002. View

Kanmaz H, Erdeve O, Emre Canpolat F, Mutlu B, Dilmen U . Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics. 2013; 131(2):e502-9. DOI: 10.1542/peds.2012-0603. View

Elbaz Y, Portnov I, Lurie-Marcu B, Shinwell E . Minimally invasive surfactant therapy intubation for surfactant delivery in preterm infant with RDS: evaluation of safety and efficacy. J Matern Fetal Neonatal Med. 2021; 35(25):6802-6806. DOI: 10.1080/14767058.2021.1924145. View

Xu C, Bao Y, Zhao J, Cheng K, Sun L, Wu J . Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China. BMC Pulm Med. 2022; 22(1):462. PMC: 9724250. DOI: 10.1186/s12890-022-02270-x. View

De Luca D, de Winter J . Less invasive surfactant administration: all that glitters is not gold. Eur J Pediatr. 2020; 179(8):1295-1296. DOI: 10.1007/s00431-020-03688-3. View

Shim G . Update of minimally invasive surfactant therapy. Korean J Pediatr. 2017; 60(9):273-281. PMC: 5638833. DOI: 10.3345/kjp.2017.60.9.273. View

10.

Kribs A, Pillekamp F, Hunseler C, Vierzig A, Roth B . Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age </=27 weeks). Paediatr Anaesth. 2007; 17(4):364-9. DOI: 10.1111/j.1460-9592.2006.02126.x. View

11.

Dargaville P, Kamlin C, Orsini F, Wang X, De Paoli A, Kanmaz Kutman H . Effect of Minimally Invasive Surfactant Therapy vs Sham Treatment on Death or Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome: The OPTIMIST-A Randomized Clinical Trial. JAMA. 2021; 326(24):2478-2487. PMC: 8715350. DOI: 10.1001/jama.2021.21892. View

12.

Attar M, Donn S . Mechanisms of ventilator-induced lung injury in premature infants. Semin Neonatol. 2002; 7(5):353-60. DOI: 10.1053/siny.2002.0129. View

13.

Aguar M, Cernada M, Brugada M, Gimeno A, Gutierrez A, Vento M . Minimally invasive surfactant therapy with a gastric tube is as effective as the intubation, surfactant, and extubation technique in preterm babies. Acta Paediatr. 2014; 103(6):e229-33. DOI: 10.1111/apa.12611. View

14.

Chang Y, Park H, Park W . The Korean Neonatal Network: An Overview. J Korean Med Sci. 2015; 30 Suppl 1:S3-S11. PMC: 4641061. DOI: 10.3346/jkms.2015.30.S1.S3. View

15.

Walsh M, Kliegman R . Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986; 33(1):179-201. PMC: 7131118. DOI: 10.1016/s0031-3955(16)34975-6. View

16.

Jobe A, Bancalari E . Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001; 163(7):1723-9. DOI: 10.1164/ajrccm.163.7.2011060. View

17.

Jena S, Bains H, Pandita A, Verma A, Gupta V, Kallem V . Surfactant therapy in premature babies: SurE or InSurE. Pediatr Pulmonol. 2019; 54(11):1747-1752. DOI: 10.1002/ppul.24479. View

18.

Victorin L, Deverajan L, Curstedt T, Robertson B . Surfactant replacement in spontaneously breathing babies with hyaline membrane disease--a pilot study. Biol Neonate. 1990; 58(3):121-6. DOI: 10.1159/000243250. View

19.

. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005; 123(7):991-9. DOI: 10.1001/archopht.123.7.991. View

20.

Venkatesh V, Ponnusamy V, Anandaraj J, Chaudhary R, Malviya M, Clarke P . Endotracheal intubation in a neonatal population remains associated with a high risk of adverse events. Eur J Pediatr. 2010; 170(2):223-7. DOI: 10.1007/s00431-010-1290-8. View